Related Experiment Videos
Secondary hyperparathyroidism and nonmedullary thyroid cancer
1Department of Surgery, Bnai Zion Medical Center, Haifa, Israel.
Israel Journal of Medical Sciences
|February 1, 1995
Summary
Secondary, uremic, hyperparathyroidism combined with non-medullary thyroid carcinoma is rare. This study suggests a potential link, highlighting factors in secondary hyperparathyroidism that may promote thyroid cancer.
Area of Science:
- Endocrinology
- Oncology
- Nephrology
Background:
- Nonmedullary thyroid carcinoma (NMTC) is associated with primary hyperparathyroidism.
- The combination of secondary, uremic, hyperparathyroidism and NMTC is exceptionally rare, with only 12 prior reported cases.
Observation:
- This report details three additional patients presenting with this rare parathyroid and thyroid disease combination.
- The co-occurrence suggests a potential etiological relationship rather than mere coincidence.
Findings:
- Factors inherent to secondary hyperparathyroidism may contribute to the induction or progression of thyroid cancer.
- Potential contributing factors include parathyroid endocrinopathy, the goiterogenic impact of sustained hypercalcemia, and uremia.
Implications:
- The findings suggest that secondary hyperparathyroidism may play a role in the development of non-medullary thyroid carcinoma.
- Associated thyroid lesions require careful consideration during parathyroid surgery in patients with secondary hyperparathyroidism.